The disrupted clinical trials of the United Kingdom coronavirus vaccine by the AstraZeneca pharmaceutical company have exposed the risks associated with the excessive reliance upon new unverified technologies, an approach that Russia finds unacceptable, Kirill Dmitriev, the head of the Russian Direct Investment Fund (RDIF), said on Saturday.
Amid the reports of the potential vaccine, Russian Federation registered 5,449 COVID-19 cases in the past 24 hours, which brings the cumulative total to 1,062,811, the country's coronavirus response centre said on Sunday.
"On September 6, the standard review process triggered a voluntary pause to vaccination across all global trials to allow review of safety data by independent committees, and worldwide regulators".
But AstraZeneca, who are working with the University of Oxford, said British authorities had now confirmed it was safe to resume trials.
The company, however, said further medical information can not be disclosed.
Zayed said the trials, which are being run in cooperation with the Chinese government and the UAE's G42 Healthcare Company, is part of an integrated package, including research on potential vaccines and manufacturing.
AstraZeneca's vaccine uses a monkey adenovirus that shares a gene with the Covid-19 coronavirus - a platform that hasn't been subjected to any long-term studies.
Turkey is considering a request from Russian Federation to conduct Phase III trials of Russia's COVID-19 vaccine, Health Minister Fahrettin Koca said on Thursday, adding a decision would be made in the next week.
An independent committee will be reviewing the safety of the vaccine.
Pauses in drug trials are commonplace and the temporary hold led to a sharp fall in AstraZeneca's share price following the announcement Tuesday.
Speaking with PUNCH HealthWise in an exclusive interview, the physician said Russian Federation "jumped the gun" by hastily approving the vaccine for use, without completing the processes vaccines undergo before they're considered safe for public use.
Unlike many vaccines, the Imperial one is completely synthetic and uses the genetic instructions for the surface spiky protein of the virus.
No details of the nature of the side effect have been given.
He cited what he described as Russia's "premature approval" of its candidate COVID-19 vaccine - Sputnik V - as reason for the statement.
"The first batches of the vaccine for testing the supply chain have already been shipped, we are now checking the delivery system so that the staff gets to know it". The phase I and Phase II trial of this vaccine have shown good immune response in older candidates of the age 60 years and above.